

LEO Pharma pipeline 2024

Continuing to build on LEO Pharma's legacy and track record for innovation

PROJECT	DESCRIPTION	INDICATIONS	PARTNERS	PRE-CLINICAL	PHASE 1	PHASE 2	PHASE 3	FILING	REGIONS
Calcipotriol LP0053	Calcipotriene and betamethasone dipronate foam	Plaque Psoriasis							 China*
Delgocitinib LP0133	Topical pan-JAK inhibitor	Chronic hand eczema							 Global
Tralokinumab** LP0162	Anti-IL-13 monoclonal antibody	Atopic Dermatitis (Pediatrics)							 Global
		Atopic dermatitis (AD on hands)							 Global
Temtokibart LP0145	Anti-IL-22RA1 monoclonal antibody	Atopic dermatitis							 Global
LEO158968 LP0189	Monoclonal antibody	Inflammatory skin diseases							 Global

Project compounds in our pipeline are investigational and have not been approved in the listed indications and regions by regulatory authorities.

**Approved in the EU and US for plaque psoriasis.*

***Approved in the EU and US for atopic dermatitis in adults and adolescents.*